開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
海灣合作委員會祕書長:海灣合作委員會-瑞士部長級會議爲推動關係開闢了更廣闊的途徑。
2026-09-22
海灣合作委員會祕書長:海灣合作委員會-瑞士部長級會議爲推動關係開闢了更廣闊的途徑。
返回
其他消息
2026-09-23
A股培育鑽石板塊震盪走強,宏昌科技漲超10%,沃爾德、四方達、英諾激光、惠豐鑽石、黃河旋風等跟漲。
A股培育鑽石板塊震盪走強,宏昌科技漲超10%,沃爾德、四方達、英諾激光、惠豐鑽石、黃河旋風等跟漲。
2026-09-23
Novo Nordisk said it is open to upgrading its U.S. listing — potentially replacing its American depositary receipts with a direct New York listing — as the Danish maker of weight‑loss drugs seeks greater U.S. visibility. Asked whether the company would consider listing shares directly on the NYSE instead of ADRs, the CEO said he saw advantages and would not rule it out but added the company is not currently studying the option. He noted rival AstraZeneca made a similar move earlier this year.
Novo Nordisk said it is open to upgrading its U.S. listing — potentially replacing its American depositary receipts with a direct New York listing — as the Danish maker of weight‑loss drugs seeks greater U.S. visibility. Asked whether the company would consider listing shares directly on the NYSE instead of ADRs, the CEO said he saw advantages and would not rule it out but added the company is not currently studying the option. He noted rival AstraZeneca made a similar move earlier this year.
Chat with us
, powered by
LiveChat